Peptides are everywhere: which longevity peptides actually work, and which are a gamble?

Reader questions answered

What are peptides, and why are they an anti-ageing trend?

Peptides are short chains of amino acids. Their sequences and structures differ, so they can have very different biological roles. The fact that one peptide works as a medicine does not mean another peptide—or a particular product containing it—will work for a different purpose.

The trend draws on a real scientific idea: molecules involved in signalling may be useful treatment targets. It also draws on marketing that turns ideas about recovery and regeneration into broad wellness promises. A longevity clinic’s promotional page illustrates those claims; it is evidence of marketing, not independent proof that its treatments improve health.

The central question is not whether a peptide sounds biologically plausible. It is whether a defined product, used in a defined way, has improved meaningful outcomes against a suitable comparison—and at what cost in side effects. No peptide discussed here has demonstrated extension of human lifespan. That conclusion reflects the evidence in this dossier, not an exhaustive audit of every peptide ever studied.

Which peptide medicines have reliable human evidence?

Insulin is an established treatment for diabetes. Certain prescribed GLP-1 medicines are supported for specific conditions, including type 2 diabetes or obesity; particular products also have cardiovascular indications for particular patients. Approval and availability depend on the product, indication and country. These medicines should not be confused with unapproved injections marketed broadly for longevity.

The strongest example in this dossier is the manufacturer-funded SELECT trial of semaglutide. It randomly assigned 17,604 adults aged at least 45, who had established cardiovascular disease and overweight or obesity but not diabetes, to semaglutide or placebo alongside standard care. Over a mean 39.8 months, cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 6.5% of the semaglutide group and 8.0% of the placebo group—a 1.5-percentage-point absolute difference.

That benefit came with a trade-off: adverse events led to permanent discontinuation in 16.6% of participants receiving semaglutide, versus 8.2% receiving placebo. The trial did not test whether healthy people live longer or whether semaglutide slows ageing generally. A systematic review also found high-certainty evidence of weight loss versus placebo over the medium term; weight loss itself is not proof of slowed ageing.

The practical distinction is between prescribing a medicine for an assessed condition and assuming that a shared peptide category makes every product a longevity treatment.

What do small copper-peptide skin studies actually show?

GHK-Cu is a copper peptide used in topical skincare. The relevant question is whether a particular formulation makes a visible difference, not whether a laboratory mechanism sounds promising.

In a randomized study after CO2 laser resurfacing, 13 patients completed follow-up. Researchers compared a skincare regimen containing GHK-Cu with one without it. At 12 weeks, blinded and computerized assessments found no significant between-group difference in redness, wrinkles or overall skin quality. Patient-reported improvement in overall skin quality favored GHK-Cu.

Those findings leave room for interest, not a definitive rejuvenation claim. The sample was small, the follow-up short, and everyone had undergone laser treatment. Patient satisfaction matters, but it does not erase the lack of a significant difference in the objective assessments. The abstract records non-US-government research support without identifying the funder.

A result for one post-procedure topical regimen cannot be generalized to every retail serum, intact skin, or an injected peptide. Larger independent comparisons on intact skin, with longer follow-up and clearly identified formulations, would make the conclusion more useful. The dossier does not verify prices or establish that any named retail brand performs like the studied regimen.

What is known about the most-hyped experimental peptides?

BPC-157: A 2025 review found very limited human orthopaedic evidence. It described a retrospective report in which seven of 12 people with chronic knee pain reported relief lasting more than six months. There was no randomized control group, so improvement cannot confidently be attributed to the peptide rather than other care, natural variation or expectations. A later systematic review concluded that BPC-157 should not be used clinically for orthopaedic and regenerative purposes outside regulated, high-quality trials. Animal results do not establish human benefit or long-term safety.

TB-500 and MOTS-c: These are promoted for recovery or longevity, but the dossier does not provide convincing human efficacy or long-term safety evidence for those claims. Regulatory discussion of a substance is not the missing clinical trial. Neither is established to extend human lifespan.

Epitalon: A 2026 narrative review distinguishes synthetic epitalon from older epithalamin preparations and found no adequately powered randomized trial establishing epitalon efficacy. Treating historical studies of a different preparation as direct proof for synthetic epitalon would overstate what is known.

Sermorelin: This peptide stimulates the growth-hormone pathway. A former US product, Geref, had a historical paediatric indication; the FDA’s historical Orange Book lists it among discontinued products and says it was not discontinued or withdrawn for safety or efficacy reasons. That history does not establish a current anti-ageing indication, benefit in healthy adults or current availability.

Thymosin alpha-1: This has more disease-specific human research than many products in the longevity market, but a disease trial is not an ageing trial. In the TESTS sepsis trial, 1,106 adults were randomized in China and 1,089 were included in the modified intention-to-treat analysis. The corrected 28-day mortality was 23.4% with thymosin alpha-1 versus 24.1% with placebo alongside standard care. The corrected hazard ratio was 0.97, with a 95% confidence interval of 0.76–1.24: no conclusive reduction. A 2025 correction updated survival and immunological data; it did not make the primary result statistically significant. The trial had public and manufacturer support. Regulatory status varies by country.

For all six, a credible longevity claim would need appropriately controlled human studies measuring meaningful outcomes and harms over time. A small positive report, a historical indication or a regulatory meeting is not a substitute.

What changed at the July and October 2026 US policy meetings?

On July 23–24, the FDA Pharmacy Compounding Advisory Committee considered specified substances for possible inclusion on the section 503A bulk-drug list. It recommended six of seven peptides considered, including BPC-157, TB-500, MOTS-c and epitalon, according to BMJ’s report.

Those were recommendations, not FDA drug approvals, completed rulemaking or automatic permission for sellers. They did not establish that the substances were effective longevity treatments.

On October 30, an HHS Federal Register notice described a draft, nonbinding interim enforcement-discretion policy for specified peptide bulk substances and specified 503A compounders while rulemaking proceeds. This is a proposed approach to enforcement, not blanket approval, automatic listing, a guarantee against enforcement or permission for research-chemical sellers to market drugs.

Anyone making a legal decision needs to check the full policy and appendices, subsequent rulemaking and applicable state requirements. The important reader takeaway is simpler: a change in a proposed enforcement approach is not proof of clinical safety or efficacy.

Why is a high-purity claim not enough for an injection?

Purity is only one part of quality. A claim about purity does not by itself establish the correct identity or concentration, sterility, absence of endotoxins, stability or suitability of the formulation. Even a well-described ingredient is not automatically a clinically tested treatment.

The FDA identifies substance-specific compounding concerns, including impurities, potential immune reactions and inadequate human safety information. Peptide impurities or aggregates may provoke immune responses; contamination and injection can cause infection. Those concerns do not mean every compounded product has caused harm, but they make a seller’s purity percentage an inadequate safety guarantee.

Compounded drugs are not individually FDA-approved. A certificate offered by a seller cannot establish the quality of a particular vial without trustworthy, relevant testing and supply-chain controls. Nor can it show that treatment works, identify interactions or reveal uncommon long-term harms.

Where can I verify a pharmacy in the US or New Zealand?

In the United States, start with FDA BeSafeRx, which directs readers to state pharmacy-board resources and describes signs of a legitimate online pharmacy. In New Zealand, check the Medsafe Pharmacy Licence Register. Before considering a personal import, read Medsafe’s import rules: requirements depend on the medicine and circumstances.

These checks answer an important but limited question. A pharmacy licence does not prove that a particular product or use is approved, effective or legal to import. Do not use a research-chemical seller’s assurances as a substitute for checking the pharmacy and discussing the actual medicine with a qualified clinician.

What should I consider instead for skin or health?

For appearance, regular sun protection and moisturizer are practical starting points. If you want more than a cosmetic improvement, discuss appropriate retinoids or procedures with a qualified clinician, including likely benefits, irritation or other risks, and whether the option fits your skin. A topical cosmetic should be judged as a topical cosmetic—not as evidence for injecting its ingredient.

For health, focus on the risks and conditions you actually have: not smoking, physical activity, adequate sleep, a balanced diet, recommended vaccinations, and management of blood pressure, cholesterol and other diagnosed risks. An appropriate prescription medicine may have much stronger evidence than an experimental injection, but the semaglutide trial also illustrates why eligibility and side effects matter.

These are general options, not a personalized treatment plan. The dossier does not provide verified treatment prices, so compare local costs directly with a licensed clinician or pharmacy rather than relying on an unverified quote.

Sources and conflicts

SELECT was funded by semaglutide’s manufacturer. The copper-peptide abstract reports non-US-government support without naming the funder. TESTS received public and manufacturer support, and its corrected results are used here. The clinic page cited above is promotional, not efficacy evidence. The 2025 BPC-157 review’s uncontrolled positive reports and the 2026 review’s caution are not contradictory: the former cannot establish causation.

The dossier was web-cited but not independently fact-checked. Its search was not exhaustive, and it did not establish a comprehensive correction or retraction audit for every paper. Further sourcing is needed for current product availability, prices, final policy and jurisdiction-specific legal advice.